Viatris Inc
VTRS: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$55.00 | Snwf | Xkfgccqz |
Viatris Reports Solid First-Quarter Results; Biosimilar Divestiture on Track for Second Half of 2022
Viatris' first-quarter results were largely within our expectations, with mid-single-digit revenue erosion across branded and generic drug categories partially offset by the realization of post-Upjohn merger cost synergies. Overall, there were few surprises during the quarter, and management reiterated its top- and bottom-line guidance targets for the year. We are maintaining our fair value estimate of $12.50 per share.